Synapse - Imaging with [(89)Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: A phase 1/2, first-in-human trial

Imaging with [(89)Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: A phase 1/2, first-in-human trial Journal Article

Authors:	Tendler, S.; Dunphy, M. P.; Agee, M.; O'Donoghue, J.; Aly, R. G.; Choudhury, N. J.; Kesner, A.; Kirov, A.; Mauguen, A.; Baine, M. K.; Schoder, H.; Weber, W. A.; Rekhtman, N.; Lyashchenko, S. K.; Bodei, L.; Morris, M. J.; Lewis, J. S.; Rudin, C. M.; Poirier, J. T.
Article Title:	Imaging with [(89)Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: A phase 1/2, first-in-human trial
Journal Title:	Lancet Oncology
Volume:	25
Issue:	8
ISSN:	1470-2045
Publisher:	Elsevier Science, Inc.
Date Published:	2024-08-01
Start Page:	1015
End Page:	1024
Language:	English
DOI:	10.1016/s1470-2045(24)00249-3
PROVIDER:	EBSCOhost
PROVIDER:	cinahl plus with full text
PUBMED:	38950555
PMCID:	PMC11656522
DOI/URL:	https://search.ebscohost.com/login.aspx?direct=true&AuthType=ip,shib&db=rzh&AN=178682524&authtype=sso&custid=s2915669&site=ehost-live&scope=site&custid=s2915669
Notes:	The MSK Cancer Center Support Grant (P30 CA008748) is acknowledged in the PDF. Corresponding MSK author is Charles M Rudin -- Source: CINAHL Plus with Full Text